A&O Shearman Supports GSK On Its AI License And Partnership With Noetik

A&O Shearman was formed in 2024 via the merger of two historic firms, Allen & Overy and Shearman & Sterling. With nearly 4,000 lawyers globally, we are equally fluent in English law, U.S. law and the laws of the world’s most dynamic markets. This combination creates a new kind of law firm, one built to achieve unparalleled outcomes for our clients on their most complex, multijurisdictional matters – everywhere in the world. A firm that advises at the forefront of the forces changing the current of global business and that is unrivalled in its global strength. Our clients benefit from the collective experience of teams who work with many of the world’s most influential companies and institutions, and have a history of precedent-setting innovations. Together our lawyers advise more than a third of NYSE-listed businesses, a fifth of the NASDAQ and a notable proportion of the London Stock Exchange, the Euronext, Euronext Paris and the Tokyo and Hong Kong Stock Exchanges.

Explore Firm Details

United Kingdom

A&O Shearman has advised GSK on its AI model licensing agreement and partnership with AI-native biotech Noetik.

Noetik will license its OCTO-VC virtual cell AI models to GSK for a minimum of five years and collaborate with GSK to create human spatial datasets relating to non-small cell lung cancer and colorectal cancer. It is an innovative commercial arrangement that supports GSK's strategy of combining its own leading AI capabilities with select third party partnerships.

Alex Shandro commented: "Working with GSK and Noetik on such an innovative arrangement underscores the strategic value of AI-enabled drug discovery and the evolving roles of AI-native biotech and pharma companies within the AI value chain. Combining cutting-edge AI technologies with GSK's established AI capabilities has the potential to accelerate insights in some of the most complex disease areas. We are proud to support a collaboration that not only advances our client's innovation agenda but also helps redefine the commercial frameworks that will shape the future of AI in biotech."

We are proud to support a collaboration that not only advances our client's innovation agenda but also helps redefine the commercial frameworks that will shape the future of AI in biotech.

Alex Shandro

Partner

The A&O Shearman team was led by AI transactions partner Alex Shandro, supported by senior associate Megan McMellon and associate Millie Fantham.

Contributor

Explore Firm Details

See More Popular Content From